20/20 OptimEyes
20/20 OptimEyes Technologies is a pre-clinical biotechnology spin-out company from McMaster University located in Hamilton, Ontario, Canada. We developed a transformative drug delivery platform for ocular diseases typically controlled by eye drops. Using a patented micelle formulation, we can change the dosing paradigm for eye drops from twice daily to once or twice weekly. Proceeds from this Summit will be used for a small batch manufacturing run to complete CMC and IND-enabling validation of the technology in our lead indication, dry eye disease. This technology will revolutionize treatment for patients, improving their comfort, compliance and clinical outcomes.
Hear more from this company during the Early Technology Showcase.
Presenter: Frances Lasowski, Founder & CEO
Read More
Able Innovations
Able Innovations is solving the painful and labour-intensive process of patient transfers by developing innovative robotic technology that enables effortless, contactless, single caregiver, safe and dignified transfers. Their DELTA Platform™, is capable of automated transfers of supine individuals who need to be moved laterally (ex. Bed to stretcher, imaging table) in healthcare facilities. With our front line staff reaching a breaking point, and facilities struggling to balance budgets- the DELTA Platform™ will result in safer working conditions for staff, and more sustainable operations for facilities as they will be able to do more with less.
Presenter: Jayiesh Singh, Chief Executive Officer
Read More
AceAge
AceAge, founded in 2015, is a revenue-generating healthcare technology company based in Burlington, ON, creating an in-home medication dispenser Karie to help people age in place and improve health outcomes. AceAge has sold over 10,000 Karie devices (contracts valued over C$28 million over 5 years), for distribution across Canada, the Netherlands, and Norway. AceAge is raising Series A capital to expand into the US, Asia and other countries across Europe. Implementation includes pharmacy integration, certification and regulatory compliance.
Presenter: Spencer Waugh, CEO
Read More
Air Microfluidic Systems Inc. (AMS)
Air Microfluidic Systems Inc. (AMS) is a startup working on developing wearable devices powered by our patent-pending air microfluidics technologies. Our current leading product is an air microfluidics-enabled active compression apparel (AMACA) for treating breast cancer-related lymphedema, which has the state-of-the-art performance while being portable with a smartphone-sized wearable control box. AMACA is at Technology Readiness Level (TRL) 5. We are at the pre-clinical stage focusing on the research and development of AMACA. The proceeds will be used for research and development from the current TRL 5 to TRL 7, pre-clinical trials (TRL 8), and commercialization (TRL 9).
Hear more from this company during the Early Technology Showcase.
Presenter: Run Ze Gao
Read More
Allarta Life Science
Allarta Life Science is a pre-clinical stage life science company, with a proprietary platform technology to enable curative cell treatments for endocrine disorders such as Lysosomal Storage Disorders/Orphan Diseases, Diabetes and Hemophilia. Allarta is raising a Pre-Series A Bridge financing to support pre-clinical studies (diabetes), determining path to Orphan Drug cell models for small and large animal studies, and R&D investment on pipeline IP and core technologies within the company.
Presenter: Harald Stover, Co-Founder & CEO
Read More
AltumView Systems
AltumView is a Vancouver AI company founded in 2016. It develops a smart sensor for applications such as senior care, security, and telehealth. The sensor monitors the activity of people such as seniors, collect health statistics, and notify caregivers when emergencies are detected, while preserving privacy. It has been in the markets of Canada, Japan, China, and Taiwan for one year. The second-generation sensor will be released in early 2021, which recently won the CES 2021 Innovation Award Honoree. The company has raised several rounds of angel funds, and is seeking new capital to scale up manufacturing, marketing, and R&D.
Presenter: Jie Liang, President and CEO
Read More
ARC Medical Devices
ARC is a clinical stage company developing the only liquid medical device that forms a barrier film to prevent surgical adhesions throughout the entire abdominopelvic cavity. Our nonclinical data show superior efficacy compared with three of the top marketed products. We are currently completing a volume escalation, safety clinical trial. Proceeds from our Series B financing will be used to start and complete a US Phase 2 efficacy and safety clinical trial in 100 patients undergoing pelvic/gynecological surgery; prosecute and maintain 8 new patent families and 3 previously issued patent families; and to support manufacturing and market access/reimbursement activities.
Presenter: Chris Springate, CEO
Read More
Axolotl Biosciences
Axolotl Biosciences strives to advance the field of medical science through the use of our novel neurobioink. We are developing innovative products that enable the 3D bioprinting of humanized tissue models to advance the field of tissue engineering and regenerative medicine. Axolotl is opening the door to new areas of research by offering the (once impossible) ability to print stem cells into 3D structures.
Presenter: Dr. Stephanie Willerth, Co-Founder
Read More
BresoTEC
BresoTEC has developed a proprietary acoustic and movement-based AI analysis platform that transforms the precision of a sleep laboratory in to a simple, cordless technology for home use. BresoTEC has completed development and will begin clinical trials early in the new year. Use of funds raised are for scale up of marketing, selling and regulatory manufacturing costs for the US market, development of the second version of the BresoDX home sleep test and scaling costs.
Presenter: Peter Bloch, CEO
Read More
ChipCare
ChipCare is a pre-revenue biotech company based in Toronto. We are in late stage development of a novel point-of-care in-vitro diagnostic platform for the differential diagnosis of infectious diseases and health monitoring. The platform includes an analyzer and single use cartridges which contain test specific reagents. The platform is intended for use in community clinics, congregate care residences, chain pharmacies, under-serviced communities etc. and provides a test result in ~ 30 minutes. This enables health care workers to provide diagnosis and treatment in a single visit, minimizing the spread of disease and delays in treatment. We expect to go to market with our initial STI assay in mid-2022.
Presenter: Jeffrey Weisberg, Chief Executive Officer and President
Read More
Curiato
Curiato is a digital health platform that is leveraging biosensing and AI to deliver patient data and insights directly from the surface of the bed to power an ecosystem of applications such as pressure injuries, heart failure, infectious disease, burns, patient safety and more. One device, multiple clinical software applications. Curiato is post revenue with successful clinical pilots, publications and Health Canada licensed. Curiatio is raising Series A capital to support US market entry, sales & marketing, and creation of additional clinical software applications.
Presenter: Moazam Khan, Co-Founder & CEO
Read More
Curovate
Curovate is revolutionizing physiotherapy by making it accessible, affordable and improving patient outcomes and adherence. Physiotherapy following orthopaedic surgery has major barriers to access due to the high cost and low adherence. This results in 80% of people not doing their rehabilitation after surgery. Curovate offers a subscription-based mobile app for rehabilitation following a total knee replacement, total hip replacement and an anterior cruciate ligament (ACL) surgery available through the Apple and Google App Stores. We are at the Seed stage seeking an investment of $200,000. This investment would be used for advertising, business to business engagement and software development.
Hear more from this company during the Early Technology Showcase.
Presenter: Nirtal Shah, CEO
Read More
Denote
Denote Therapeutics is developing the allogeneic Double Negative T-cell (DNT) platform for off-the-shelf therapeutics in oncology and certain immune disorders. Denote plans to advance this platform through the development of both unmodified and modified DNT therapies both in-house and in conjunction with partners.
Hear more from this company during the Early Technology Showcase.
Presenter: Robert Verhagen, CEO
Read More
DNAMx
DNAMx is a cross-border molecular diagnostics start-up company being spun out of University Health Network. Scientific co-founders from Princess Margaret Cancer Research Institute, Daniel De Carvalho (Interim CSO) and Scott Bratman (CEO), have joined forces with serial entrepreneurs, Anne-Renee Hartman (CMO), David Scheer (Board Chair), and Maneesh Jain (Board Member), to commercialized cutting-edge liquid biopsy technology for cancer detection and management. Building on multiple high-impact publications in Nature and Nature Medicine, DNAMx is now raising a large Series A financing round to achieve ambitious milestones aimed at bringing the technology into the clinic.
Hear more from this company during the Early Technology Showcase.
Presenter: Scott Bratman, Founder & CEO
Read More
Elarex
Elarex is commercializing its proprietary PT120 formulation technology, proven to stabilize vaccines and biotherapeutics so that cold chain distribution is no longer required. We recently secured $500k in pre-seed financing (another $400k pending) and were awarded NSERC I2I Grant. Our technical team is assembled and we have three paid pilots ongoing with top tier vaccine manufacturer. Business Development leader added to team. We are seeking $4,000,000 to aggressively pursue mRNA/LNP opportunity,expand leadership and technical team, enhance IP portfolio, and expand number of partners and projects.
Presenter: Robert DeWitte, Co-Founder and CEO
Read More
Feldan Therapeutics
Feldan Therapeutics is a biotechnology company that introduced the Feldan Shuttle, a peptide-based platform that allows safe and efficient delivery of proteins, peptides and small molecules inside cells. This technology has the potential to help treat many diseases by targeting intracellular pathways. Feldan is focused on bringing its two therapeutic applications (topical product for BCC/Gorlin patients and inhaled CRISPR-based therapy for Cystic Fibrosis) to the clinic. The company is looking to raise its Series B round of financing mid-2021 to finance Phase I/II clinical trial of our first-to-human indication (Gorlin syndrome) as well as the pre-clinical phase of our Cystic Fibrosis indication.
Presenter: Francois-Thomas Michaud, Chief Executive Officer
Read More
Huron Digital Pathology
With a first-of-its-kind, AI-enabled image search engine called Lagotto, Huron Digital Pathology is revolutionizing how pathologists access the vast knowledge contained in the world’s pathology reports, hospital records, and clinical data, to drive efficiency and reduce diagnostic error. We just gained our first high profile customer for Lagotto in the US and are beginning to generate recurring software revenue. We are actively engaging with large hospitals and institutions keen to benefit from our solution. We are raising a Series A round to scale our sales efforts, expand our product portfolio and achieve regulatory approvals.
Presenter: Patrick Myles, Chief Executive Officer
Read More
Innovakine
Using cutting-edge protein and cell engineering approaches, Innovakine has developed a proprietary platform technology that allows clinicians to send exclusive, customized signals to immune cells and other cell types anywhere in the body, with broad clinical applications in the fields of cancer immunotherapy, infectious disease, autoimmunity, transplantation and regenerative medicine. Innovakine was founded in 2019 by Brad Nelson PhD (Distinguished Scientist, British Columbia Cancer; Professor, UBC) and Martin Boulanger PhD (Professor, University of Victoria) following a successful research collaboration with Zymeworks Inc., a clinical-stage biotechnology company. Innovakine is raising $4M in seed funding to complete pre-clinical POC studies in murine solid tumor models.
Presenter: Brad Nelson, Co-founder and CEO
Read More
Inspire Biotherapeutics
Inspire Biotherapeutics is a new company founded in partnership with The University of Guelph and The Ottawa Hospital Research Institute to develop and commercialize transformative gene therapies for currently incurable mono-genetic lung diseases. We have access to a GMP viral vector manufacturing facility and integrated research and clinical care platform. Our approach is based on recent successes in gene therapy development and commercialization: our proprietary, rationally designed adeno-associated virus (AAV) capsid, can be viewed as a next generation gene therapy and has many advantages over current products. Proceeds will be used to develop our first pipeline product to be tested in clinical trials by 2022.
Presenter: Bernard Thébaud, President
Read More
IntelliStem
IntelliStem is an early stage biotech company that has created the next generation of cell therapy products to target catastrophic diseases such as cancer and Infectious diseases. Its first product “Super Sentinel CellsTM” is an off-the-shelf product to target cancer that has shown an 80% success rate compared to 20% of incumbents In-vivo, which can target both blood and solid tumors offering scalable and more efficacious solutions, at a fraction of the cost of the current platforms. We hope to use investor funds to advance our assets to market through clinical trials, then out-licensing and co-development.
Presenter: Riam Shammaa, Chief Executive Officer and Co-Founder
Read More
